The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), a Double-blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Protocol No
ALLIANCE-A011801
Principal Investigator
Lubna Chaudhary
Phase
III
Summary
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Description
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Participating Institutions
Drexel Town Center
Froedtert Hospital
Froedtert West Bend Hospital
Froedtert Menomonee Falls Hospital
Status
OPEN TO ACCRUAL
Sub Category
Breast Cancers
ClinicalTrials.gov
go to website